{"id":"W2954226397","doi":"10.1182/blood.2019003127","title":"Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":112,"is_retracted":false,"has_abstract":true,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia","funders":"Takeda Oncology","keywords":"ABVD; Dacarbazine; Brentuximab vedotin; Medicine; Vinblastine; Bleomycin; Internal medicine; Chemotherapy regimen; Population; Progression-free survival; Nuclear medicine; Oncology; Surgery; Chemotherapy; Lymphoma; Vincristine; Hodgkin lymphoma; Cyclophosphamide","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01165465,0.000347365,0.001487219,0.0004440334,0.0002582685,0.001362271,0.0007015995,0.0009329066,0.0007185891],"category_scores_gemma":[0.004441465,0.00024929,0.001264639,0.001031976,0.0002845746,0.0009402268,0.0004153912,0.00173006,0.0001569264],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008153897,"about_ca_system_score_gemma":0.001043535,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009136507,"about_ca_topic_score_gemma":0.003247422,"domain_scores_codex":[0.9981607,0.001043512,0.0002214953,0.0001033202,0.0003457456,0.0001252594],"domain_scores_gemma":[0.9942879,0.002523456,0.001433147,0.0003536241,0.0006197511,0.0007820727],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.1234138,0.003498141,0.08997945,0.003209714,0.00470659,0.0003226559,0.0004829657,0.002460513,0.01107644,0.0007285564,0.01395268,0.7461685],"study_design_scores_gemma":[0.1119679,0.1456394,0.5105243,0.002055839,0.01441044,0.002284562,0.000485935,0.003269697,0.008736243,0.001562635,0.1988977,0.0001652736],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.7871438,0.1969393,0.001616062,0.004332303,0.0007510831,0.0008263671,0.003031637,0.0001111319,0.005248313],"genre_scores_gemma":[0.9015023,0.07526395,0.004028425,0.008219432,0.001161076,0.001005126,0.00670651,0.00008433317,0.002029009],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01165465,"threshold_uncertainty_score":0.06163639,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01647671811408724,"score_gpt":0.2523826619715569,"score_spread":0.2359059438574697,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}